Lead Product(s) : Gefitinib
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : China-Japan Friendship Hospital | Peking University Cancer Hospital & Institute | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Chinese PLA General Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Gefitinib is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Lung Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 22, 2017
Lead Product(s) : Gefitinib
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : China-Japan Friendship Hospital | Peking University Cancer Hospital & Institute | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Chinese PLA General Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Gefitinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 30, 2017
the Clinical Trial of Gefitinib(Non - Small Cell Lung Cancer)
Details : Gefitinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 29, 2017
Lead Product(s) : Gefitinib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable
Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer
Details : Gefitinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 21, 2017
Lead Product(s) : Gefitinib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Gefitinib
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioequivalence Study of Gefitinib Tablets Under Fasting Conditions
Details : Gefitinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 10, 2017
Lead Product(s) : Gefitinib
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Gefitinib
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioequivalence Study of Gefitinib Tablets Under Fed Conditions
Details : Gefitinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 10, 2017
Lead Product(s) : Gefitinib
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Gefitinib
Therapeutic Area : Oncology
Study Phase : Phase II/ Phase III
Sponsor : AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Gefitinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 29, 2014
Lead Product(s) : Gefitinib
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Sponsor : AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Gefitinib
Therapeutic Area : Oncology
Study Phase : Phase IV
Sponsor : AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Gefitinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 24, 2014
Lead Product(s) : Gefitinib
Therapeutic Area : Oncology
Highest Development Status : Phase IV
Sponsor : AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Gefitinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 02, 2014
Lead Product(s) : Gefitinib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable
MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC).
Details : Gefitinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 14, 2014
Lead Product(s) : Gefitinib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
